- TRADE NAMES: Remodulin (United Therapeutics); Tyvaso (United Therapeutics)
- INDICATIONS: Pulmonary arterial hypertension, patients requiring transition from epoprostenol
- SYNONYM: Treprostinil palmitil (an ester prodrug)
- CLASS: Antihypertensive, Platelet aggregation inhibitor, Prostaglandin
- HALF-LIFE: 2–4 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Antihypertensives, CYP2C8 inhibitors or inducers, Diuretics, Gemfibrozil, Meloxicam, Rifampin, Rifapentine, Vasodilators
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of treprostinil in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/12/2024
